These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2571233)

  • 1. Sebum secretion in idiopathic Parkinson's disease: effect of anticholinergic and dopaminergic drugs.
    Villares JC; Carlini EA
    Acta Neurol Scand; 1989 Jul; 80(1):57-63. PubMed ID: 2571233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [L-dopa, biperiden and sebum excretion in Parkinson disease].
    Villares JC
    Arq Neuropsiquiatr; 1989 Mar; 47(1):31-8. PubMed ID: 2764750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study.
    Avorn J; Bohn RL; Mogun H; Gurwitz JH; Monane M; Everitt D; Walker A
    Am J Med; 1995 Jul; 99(1):48-54. PubMed ID: 7598142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism.
    Priori A; Berardelli A; Inghilleri M; Accornero N; Manfredi M
    Brain; 1994 Apr; 117 ( Pt 2)():317-23. PubMed ID: 8186958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease.
    Wolters EC; Calne DB
    CMAJ; 1989 Mar; 140(5):507-14. PubMed ID: 2563667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 8. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography.
    Tedroff J; Aquilonius SM; Laihinen A; Rinne U; Hartvig P; Anderson J; Lundqvist H; Haaparanta M; Solin O; Antoni G
    Acta Neurol Scand; 1990 Jan; 81(1):24-30. PubMed ID: 2330812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-dopa and the secretion of sebum in Parkinsonian patients.
    Streifler M; Avrami E; Rabey JM
    Eur Neurol; 1980; 19(1):43-8. PubMed ID: 7371653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.
    Cooper JA; Sagar HJ; Doherty SM; Jordan N; Tidswell P; Sullivan EV
    Brain; 1992 Dec; 115 ( Pt 6)():1701-25. PubMed ID: 1486457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    J Maine Med Assoc; 1977 Apr; 68(4):134-41, 146. PubMed ID: 845500
    [No Abstract]   [Full Text] [Related]  

  • 13. Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease.
    Rabey JM; Oberman Z; Scharf M; Isakov M; Bar M; Graff E
    Acta Neurol Scand; 1990 May; 81(5):411-5. PubMed ID: 2375243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Parkinsonian syndrome. Etiology, diagnosis, treatment].
    Montastruc JL
    Rev Prat; 1990 Nov; 40(27):2555-9. PubMed ID: 1980547
    [No Abstract]   [Full Text] [Related]  

  • 15. Sebum excretion in Parkinsonism.
    Burton JL; Cartlidge M; Cartlidge NE; Shuster S
    Br J Dermatol; 1973 Mar; 88(3):263-6. PubMed ID: 4268246
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antiparkinsonian drugs].
    Rascol A; Montastruc JL; Rascol O
    Rev Prat; 1989 Mar; 39(8):663-9. PubMed ID: 2567051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine controls Parkinson's tremor by inhibiting the cerebellar thalamus.
    Dirkx MF; den Ouden HE; Aarts E; Timmer MH; Bloem BR; Toni I; Helmich RC
    Brain; 2017 Mar; 140(3):721-734. PubMed ID: 28073788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
    Taniguchi R; Nakagawasai O; Tan-no K; Yamadera F; Nemoto W; Sato S; Yaoita F; Tadano T
    Biosci Biotechnol Biochem; 2013; 77(2):266-70. PubMed ID: 23391905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.